| Name | UC2288 |
| Description | UC2288 is a relatively selective p21 attenuator which is synthesized based Sorafenib. UC2288 attenuates p21 protein levels with minimal effect on p21 protein stability. |
| In vitro | UC2288 (0-10 μM; 24 hours) reduces p21 mRNA expression through transcriptional or post-transcriptional mechanisms, independent of p53, with no inhibition of VEGFR2 and Raf kinases, even at 10 μM[1]. |
| In vivo | UC2288 (10 mg/kg; i.p.) attenuates MPTP-induced behavioral impairment, prevents activation of MAPK pathway in the MPTP-treated mice brain. MPTP treatment raises TNF-α, IL-6 and IL-1β levels in MPTP treated mice brain, but UC2288 signicantly decreases MPTP-induced TNF-α, IL-6 levels, but IL-1β is not decreased in brain[2].UC2888 (15 mg/kg; oral) co-treatment with imetelstat significantly suppresses tumor growth and does not effect mice weight[3]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 48 mg/mL (99.62 mM), Sonication is recommended. 10% DMSO+90% Corn Oil : 2 mg/mL (4.15 mM), Sonication is recommended.
|
| Keywords | UC-2288 | UC2288 | UC 2288 | sorafenib | RCC | p53-mutant | p21 | ovarian | MDM-2/p53 | Inhibitor | inhibit | HK2 | cancer | Attenuator | 786-O |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Ferroptosis Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Anti-Cancer Metabolism Compound Library | Pyroptosis Compound Library | Orally Active Compound Library | PPI Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Covalent Inhibitor Library | Anti-Cancer Compound Library |